Research programme: bispecific antibodies - Immune Pharmaceuticals

Drug Profile

Research programme: bispecific antibodies - Immune Pharmaceuticals

Alternative Names: Tetravalent bsAb - Immune Pharmaceuticals; Tetravalent IgG1-like bispecific antibody - Immune Pharmaceuticals

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Immune Pharmaceuticals Inc
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action B-cell maturation antigen modulators; CD274 antigen modulators; OX40 receptor modulators; PDCD 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Renal cell carcinoma

Most Recent Events

  • 23 Jan 2017 Immune Pharmaceuticals enters into an exclusive sub-licensing agreement with SATT Sud Est for the development and commercialisation of mono- and bi-specific antibodies for Cancer
  • 23 Jan 2017 Preclinical trials in Renal cell carcinoma in France (Parenteral)
  • 22 Mar 2016 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top